|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61K 31/175 | (2006.01) | ||
| A61K 31/495 | (2006.01) | ||
| A61K 38/19 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 14/525 | (2006.01) | ||
| C07K 16/18 | (2006.01) | ||
| A61K 45/06 | (2006.01) |
| (11) | Number of the document | 4153232 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21726426.6 |
| Date of filing the European patent application | 2021-05-24 | |
| (97) | Date of publication of the European application | 2023-03-29 |
| (45) | Date of publication and mention of the grant of the patent | 2024-06-26 |
| (46) | Date of publication of the claims translation | 2024-10-10 |
| (86) | Number | PCT/EP2021/063758 |
| Date | 2021-05-24 |
| (87) | Number | WO 2021/234178 |
| Date | 2021-11-25 |
| (30) | Number | Date | Country code |
| 20176157 | 2020-05-22 | EP |
| (72) |
HEMMERLE, Theresa , CH
|
| (73) |
Philogen S.p.A. ,
La Lizza 7, 53100 Siena,
IT
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | TNFα imunokonjugato terapija, skirta smegenų auglių gydymui |
| TNF-A IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORS |
| Payment date | Validity (years) | Amount | |
| 2025-05-05 | 5 | 115.00 EUR |
| 2026-05-24 |